Kimia Biosciences Ltd

Kimia Biosciences Limited has announced its 33rd Annual General Meeting (AGM) scheduled for Monday, September 28, 2026, at 03:00 P.M. (IST) via Video Conferencing/Other Audio-Visual Means. The company will transact businesses as outlined in the AGM notice. The Annual Report for the financial year 2025-26, along with the AGM notice, is being sent electronically to shareholders and will be available on the company's website, BSE, and NSDL e-Voting platform. The report highlights the company's R&D objectives, including investments in drug research and development to address unmet patient needs. A significant achievement mentioned is the grant of a patent in January 2026 for Luliconazole, an antifungal drug.

Kimia Biosciences Ltd has announced the details for its 33rd Annual General Meeting (AGM). The cut-off date for determining voting eligibility for both remote e-voting and the AGM has been set as Monday, September 21, 2026. The remote e-voting period will commence on Friday, September 25, 2026, at 9:00 AM and conclude on Sunday, September 27, 2026, at 5:00 PM. The 33rd AGM is scheduled for Monday, September 28, 2026, at 3:00 PM. Shareholders registered by the cut-off date will be eligible to participate in the voting process, which is facilitated through the National Securities Depository Limited (NSDL).

Kimia Biosciences Ltd has announced its 33rd Annual General Meeting (AGM) will be held on September 28, 2026, at 3:00 PM IST. The meeting will be conducted through Video Conferencing/Other Audio Visual Means (VC/OAVM). The company will submit its Annual Report for the financial year 2025-26 along with the AGM notice. The notice and report will be sent electronically to members and will also be available on the company's website, BSE, and NSDL e-Voting platform. The report highlights R&D advancements, including a patent grant for Luliconazole in January 2026.

Kimia Biosciences Limited's Board of Directors met on September 3, 2026, approving several key appointments and proposals for the upcoming 33rd Annual General Meeting (AGM). The board re-appointed Mr. Sameer Goel as Director and appointed Mr. Amulya Kumar Nayak as Non-Executive Director. Ms. Reema Goyal and Mr. Avinash Prabhat were appointed as Non-Executive Independent Directors for five-year terms. The board also approved remuneration for cost auditors, took note of the cost audit report for FY25-26, and approved proposals to increase borrowing limits, create mortgages, and make loans/guarantees, all subject to member approval at the AGM. The notice for the 33rd AGM, scheduled for September 28, 2026, was also approved, along with the Board's Report and the 33rd Annual Report for FY25-26.

Kimia Biosciences Ltd announced the approval of its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors met on August 10, 2026, to take on record the standalone financial results and the limited review report from the statutory auditors. The company operates within a single primary business segment, Pharmaceuticals.

Kimia Biosciences Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved and took on record the results at a meeting held on August 10, 2026. A limited review report from the statutory auditors was also placed before the board. The company's primary business segment is Pharmaceuticals.

Kimia Biosciences Ltd has announced that its Board of Directors will convene on August 10, 2026. The primary agenda item for this meeting is to consider and approve the Un-Audited Financial Results for the first quarter ended June 30, 2026. The company has also informed about the closure of the trading window for designated persons from July 1, 2026, until 48 hours after the declaration of these financial results.

Kimia Biosciences Limited's Board of Directors convened on August 1, 2026, approving key auditor appointments and discontinuances. M/s Mahesh Singh & Co. were appointed as Cost Auditors for FY 2026-27, and M/s Chaudhry & Associates as Internal Auditors for the same period. Additionally, M/s Maya Sharma and Associates were appointed as Secretarial Auditors for FY 2025-26 and 2026-27. The board also approved the discontinuance of M/s M & Co. as Secretarial Auditor, effective August 1, 2026.

Kimia Biosciences Ltd has announced the closure of its trading window for dealing in the company's equity shares. This closure is effective from July 1, 2026, and will continue until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. The measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be closed for all promoters, directors, designated persons, and their immediate relatives. The company will separately announce the date of the Board of Directors' meeting to consider these financial results.

Kimia Biosciences Ltd. approved its audited standalone financial results for the financial year ended March 31, 2026, during a board meeting held on May 29, 2026. The results, along with the Independent Auditor’s Report, were reviewed and taken on record by the Board of Directors. The meeting commenced at 3:55 p.m. and concluded at 4:35 p.m. The auditor's report indicates a true and fair view of the company's state of affairs, profit, other comprehensive income, changes in equity, and cash flows for the specified period.